Peptide Research Week in Review: 2-8 September 2026

What Happened in Peptide Research This Week (2-8 Sep 2026)?

Six separate items published across the week, none of them a retatrutide trial readout but all of them bearing on the same underlying story: a licensed dual agonist expanding its approved uses, an unlicensed triple agonist attracting more counterfeiters and more regulatory attention the closer it gets to filing, and the commercial and enforcement infrastructure around GLP-1-class peptides continuing to harden on both sides of the Atlantic. Tirzepatide (Mounjaro) picked up a new FDA cardiovascular-risk-reduction indication.[1] Coverage recapped the MHRA's dismantling of three illegal UK manufacturing operations producing counterfeit retatrutide and tirzepatide pens.[3] Clarivate's Drugs to Watch 2026 update projected retatrutide toward roughly $30bn in 2031 sales.[5] The FDA sent warning letters to five online sellers marketing unapproved retatrutide and tirzepatide products.[6] A BBC investigation detailed organised-crime networks manufacturing counterfeit retatrutide at industrial scale.[8] And Fierce Pharma's oral GLP-1 tracker recorded record US weekly prescriptions for both licensed pills, Wegovy and Foundayo.[10]

Read together, the week has a clear shape: the licensed pharmaceutical pipeline (tirzepatide's label expansion, the two oral pills' prescription growth) is moving in one direction, while the unlicensed retatrutide supply chain (counterfeit manufacturing, warning letters, organised crime) is moving in a parallel and increasingly adversarial one. Retatrutide itself has still not been evaluated for safety or efficacy by the FDA or MHRA.

What Did Tirzepatide's New FDA Indication Cover?

Tirzepatide is a licensed pharmaceutical, approved and marketed by Eli Lilly — the mechanism is relevant to research on the dual GIP/GLP-1 pathway, but this indication has no bearing on the regulatory status of any research-use compound. It is worth distinguishing clearly from retatrutide, Lilly's investigational triple agonist (GIP/GLP-1/glucagon), which remains unapproved everywhere and is the compound most of the rest of this week's news concerns.[2]

What Has the MHRA's Enforcement Record Actually Found?

This is enforcement history, not a new raid this week — but it resurfaced in trade coverage the same week as the BBC's organised-crime investigation (below), and the pairing illustrates the same point twice: the products the MHRA has seized are unlicensed pens manufactured for injection and sold as finished medicines, entirely distinct from HPLC-verified powder sold, labelled and documented as an in vitro laboratory reagent.[4]

What Does Clarivate's $30bn Retatrutide Forecast Assume?

A commercial analyst forecast is a projection built on Lilly's own Q1 2027 BLA timeline and the TRIUMPH programme's published Phase 3 results — it is not itself new trial data, and every figure in it assumes an approval that has not yet happened. It is a useful gauge of how the pharmaceutical-analyst community currently reads the programme's odds, nothing more.

Who Did the FDA Send Warning Letters to This Week?

The FDA's stated concern in each letter is the same recurring trigger seen throughout 2026: dosing instructions, therapeutic claims and human-use framing on sites nominally selling "research use only" material, not the underlying legality of research peptides as laboratory reagents.[7] See our guide on whether research peptides are legal for how the same distinction applies under UK law.

What Did the BBC's Counterfeit Retatrutide Investigation Find?

This is the same demand-outrunning-supply pattern this site has tracked since Lilly's first black-market lawsuits in August:[9] a compound with no approved product anywhere in the world attracts counterfeiters precisely because there is no legitimate finished-dose alternative to buy. It has no bearing on genuine research-reagent supply chains, which sell unreconstituted powder for laboratory use, with batch documentation available on request and no dosing or human-use instructions.

How Are the Two Licensed Oral GLP-1 Pills Performing Commercially?

This is commercial prescription-volume data for two approved medicines, not a research finding about any investigational compound — but the growth curve is a useful reference point for how quickly an approved oral GLP-1 can scale once it clears the FDA, context worth keeping in mind against Clarivate's retatrutide forecast above.

How Do This Week's Stories Connect?

Clarivate's $30bn forecast sits at the hinge between the two tracks: it assumes retatrutide eventually joins the licensed column, on Lilly's own Q1 2027 BLA timeline, but until then the compound continues to generate exactly the kind of unlicensed-market activity this week's enforcement stories describe.

What Happens Next?

What Should UK and Irish Researchers Take From This Week?

None of this week's six stories changes the regulatory status of research peptides in the UK or Ireland. Tirzepatide's indication expansion and the oral-pill prescription data concern licensed pharmaceuticals; the MHRA enforcement recap, the FDA warning letters and the BBC investigation all concern unlicensed products manufactured or marketed for human use, not laboratory reagents; and Clarivate's forecast is an analyst projection, not new evidence. See our guide on whether research peptides are legal in the UK for the fuller regulatory picture, and retatrutide's mechanism of action for the pharmacology behind the compound driving most of this week's coverage.

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA, HPRA or FDA. Not for human or veterinary consumption. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions